Gunnar Birgegård Selected Research

anagrelide (Agrylin)

9/2021	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.
1/2018	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
10/2016	The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
4/2014	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
1/2013	Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: results of a prospective long-term follow-up.
4/2008	TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.
1/2007	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
5/2004	Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gunnar Birgegård Research Topics

Disease

15	Neoplasms (Cancer) 01/2018 - 01/2005
8	Anemia 04/2016 - 01/2005
6	Primary Myelofibrosis (Myelosclerosis) 01/2020 - 11/2006
6	Essential Thrombocythemia 01/2018 - 09/2006
5	Thrombocytosis (Thrombocythemia) 09/2021 - 05/2004
4	Polycythemia Vera 01/2020 - 09/2006
4	Hemorrhage 01/2018 - 01/2009
4	Stomatitis 02/2015 - 10/2007
3	Thrombosis (Thrombus) 01/2020 - 07/2013
3	Pain (Aches) 02/2015 - 10/2007
3	Iron Deficiencies 12/2014 - 04/2008
3	Myeloproliferative Disorders (Myeloproliferative Disorder) 04/2008 - 05/2004
2	Leukemia 01/2020 - 01/2018
2	Fatigue 04/2016 - 03/2010
2	Mucositis 08/2010 - 10/2007
1	von Willebrand Diseases (von Willebrand's Disease) 09/2021
1	Disease Progression 01/2020
1	Hypophosphatemia 04/2016
1	Drug-Related Side Effects and Adverse Reactions 04/2016
1	Nausea 01/2015
1	Vomiting 01/2015
1	Myocardial Infarction 01/2013
1	Heart Failure 01/2013
1	Iron Overload 09/2011
1	Infections 08/2010
1	Lymphoma (Lymphomas) 03/2010
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 03/2010
1	Ulcer 01/2009
1	Fibrosis (Cirrhosis) 01/2007
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2006
1	Hodgkin Disease (Hodgkin's Disease) 11/2006
1	Colorectal Neoplasms (Colorectal Cancer) 01/2006

Drug/Important Bio-Agent (IBA)

8	anagrelide (Agrylin)FDA LinkGeneric 09/2021 - 05/2004
5	HematinicsIBA 04/2016 - 04/2008
5	Hemoglobins (Hemoglobin)IBA 12/2014 - 01/2005
4	Pharmaceutical PreparationsIBA 10/2016 - 05/2004
3	IronIBA 04/2016 - 04/2008
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 06/2015 - 01/2009
2	Opioid Analgesics (Opioids)IBA 02/2015 - 10/2007
2	Ferritins (Ferritin)IBA 12/2014 - 09/2011
2	CytokinesIBA 04/2008 - 01/2005
2	PlatinumIBA 11/2006 - 01/2006
1	Interferon-alpha (Interferon Alfa)IBA 09/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Janus Kinase 2IBA 01/2020
1	Sulfates (Sulfates, Inorganic)IBA 04/2016
1	Phosphates (Orthophosphate)IBA 04/2016
1	iron isomaltoside 1000IBA 04/2016
1	SolutionsIBA 02/2015
1	C-Reactive ProteinIBA 02/2015
1	antineoplaston A10 (A 10)IBA 02/2015
1	AntiemeticsIBA 01/2015
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2015
1	Aprepitant (Emend)FDA Link 01/2015
1	Serotonin 5-HT3 Receptor AntagonistsIBA 01/2015
1	ferric carboxymaltoseIBA 12/2014
1	Transferrin (beta 2 Transferrin)IBA 12/2014
1	Thalidomide (Thalomid)FDA Link 06/2014
1	AndrogensIBA 06/2014
1	diethylstilbestrol monophosphate (PDES)IBA 01/2013
1	Cytostatic AgentsIBA 12/2012
1	Syntex adjuvant formulationIBA 03/2012
1	AlbuminsIBA 08/2010
1	epoetin betaIBA 01/2007
1	Reticulin (Reticular Fiber)IBA 01/2007
1	Erythropoietin FDA Link 01/2007
1	InterferonsIBA 09/2006

Therapy/Procedure

10	Therapeutics 09/2021 - 01/2005
9	Drug Therapy (Chemotherapy) 04/2016 - 01/2005
4	Cryotherapy (Therapy, Cold) 02/2015 - 10/2007
3	Stem Cell Transplantation 02/2015 - 11/2006
2	Total Parenteral Nutrition 02/2015 - 08/2010
2	Bone Marrow Transplantation (Transplantation, Bone Marrow) 08/2010 - 10/2007
1	Duration of Therapy 02/2015
1	Homologous Transplantation 11/2006
1	Radiotherapy 01/2005